GGrantIndex
Sort

64,565 grants matching drug discovery

Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate Cancer

$643,148
Jindan Yu · Emory University · R01 · FY2025 · CA

Reconfigurable microfluidic assay platform for molecular library screening

$643,058
Peter Russell Charles Gascoyne · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · EB

Small-molecule STAT3 degraders

$643,055
Shaomeng Wang · University Of Michigan At Ann Arbor · R01 · FY2020 · CA

Identification of REV-ERB inverse agonists for cancer immunotherapy

$643,014
Laura A Solt · Scripps Florida · R01 · FY2020 · CA

PRETARGETING WITH ANTI-CEA MABS FOR THERAPY

$642,945
Paul Yazaki · Beckman Research Institute/City Of Hope · P01 · FY2009 · CA

Broad-spectrum therapeutics against SARS-CoV-2 3CL protease

$642,901
Raymond F. Schinazi · Emory University · R01 · FY2025 · AI

Accelerating the Discovery of Antifungal Peptides with OBOC Combinatorial Technology.

$642,775
Angela Gelli · University Of California At Davis · R56 · FY2025 · AI

Impact of RNAi and unisexual reproduction on Cryptococcus evolution, drug resistance, and pathogenesis

$642,774
Joseph Heitman · Duke University · R01 · FY2021 · AI

Research Infrastructure Core

$642,765
Timothy Moore · Florida Agricultural And Mechanical Univ · U54 · FY2021 · MD

Impact of RNAi and unisexual reproduction on Cryptococcus evolution, drug resistance, and pathogenesis

$642,748
Joseph Heitman · Duke University · R01 · FY2022 · AI

Development of screens for drugs in alcohol dependence

$642,748
John M Littleton · University Of Kentucky · R01 · FY2006 · AA

Impact of RNAi and unisexual reproduction on Cryptococcus evolution, drug resistance, and pathogenesis

$642,695
Joseph Heitman · Duke University · R01 · FY2023 · AI

Impact of RNAi and unisexual reproduction on Cryptococcus evolution, drug resistance, and pathogenesis

$642,695
Joseph Heitman · Duke University · R01 · FY2025 · AI

Impact of RNAi and unisexual reproduction on Cryptococcus evolution, drug resistance, and pathogenesis

$642,695
Joseph Heitman · Duke University · R01 · FY2024 · AI

Drug Abuse: Discovering Ligands for Pertinent GPCRs

$642,616
Marc G. Caron · Duke University · P30 · FY2016 · DA

Defining an Obesity QTL on Chromosome 3q

$642,570
Xiaofeng Zhu · Case Western Reserve University · R01 · FY2007 · HL

Roles of Noncoding RNA in Bone Regeneration

$642,531
Jake Jinkun Chen · Tufts University Boston · R01 · FY2021 · DE

Fluorescence System for Sensing Biospecific Interactions

$642,455
Bioelectrospec, Inc. · R44 · FY2002 · RR

E7 TCR-T cell therapy for HPV-associated cancers

$642,086
Christian Hinrichs · Rutgers Biomedical And Health Sciences · U01 · FY2024 · CA

Leveraging electronic medical records to perform large-scale diabetes pharmacogenomics among ancestrally diverse patient populations

$642,048
Keoki Williams · Henry Ford Health System · R01 · FY2017 · DK

Drug Abuse: Discovering Ligands for Pertinent GPCRs

$642,037
Marc G. Caron · Duke University · P30 · FY2015 · DA

Molecular characterization of myeloma and related asymptomatic precursor states

$642,027
Elizabeth E Brown · University Of Alabama At Birmingham · R01 · FY2014 · CA

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale Modeling

$642,003
Thomas E Ferrin · University Of California, San Francisco · R01 · FY2019 · GM

^Identification of novel secondary metabolites produced by symbiotic Proteobacte

$641,924
Jon Clardy · University Of Wisconsin-Madison · U19 · FY2014 · AI

Inflammation and cancer treatment

$641,901
David Wink · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA